Compare LLY & MCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LLY | MCD |
|---|---|---|
| Founded | 1876 | 1940 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 204.6B |
| IPO Year | 2007 | 1996 |
| Metric | LLY | MCD |
|---|---|---|
| Price | $1,126.67 | $268.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 29 |
| Target Price | ★ $1,218.84 | $344.17 |
| AVG Volume (30 Days) | 2.4M | ★ 4.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | 0.81% | ★ 2.56% |
| EPS Growth | ★ 95.99 | 4.92 |
| EPS | ★ 8.26 | 2.78 |
| Revenue | ★ $65,179,000,000.00 | $26,885,000,000.00 |
| Revenue This Year | $27.15 | $7.65 |
| Revenue Next Year | $16.04 | $6.00 |
| P/E Ratio | $135.18 | ★ $98.53 |
| Revenue Growth | ★ 44.70 | 3.72 |
| 52 Week Low | $623.78 | $270.08 |
| 52 Week High | $1,182.73 | $341.75 |
| Indicator | LLY | MCD |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 35.20 |
| Support Level | $1,032.70 | N/A |
| Resistance Level | $1,165.92 | $311.08 |
| Average True Range (ATR) | 32.52 | 5.40 |
| MACD | -7.42 | -0.86 |
| Stochastic Oscillator | 41.11 | 13.31 |
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
McDonald's is the world's largest restaurant brand, with nearly $139 billion in systemwide sales across more than 45,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 62%), with the remainder stemming from company-operated restaurants across three segments: the United States (39% of systemwide sales), international operated markets (35%), and international developmental/licensed markets (26%).